0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)."/> 0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)."/> 0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)." /> 0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)." />
Sat, 29 Mar 2025

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Bulletin.

More Information
null in null

International

Section
World mobilizes assistance for quake-hit Myanmar
Myanmar earthquake death toll expected to rise

The death toll in Friday's massive earthquake in Myanmar has risen to nearly 700, and is expected to rise significantly. At least another...

US boosts egg imports from Brazil amid bird flu spread
US turns to Brazil, other sources for eggs during bird flu outbreak

WASHINGTON, D.C.: In response to soaring egg prices and supply shortages driven by a devastating bird flu outbreak, the United States...

Trump pledges more nations will join Abraham Accords
Trump predicts more countries will be added to Abraham Accords

WASHINGTON, D.C.: U.S. President Donald Trump vowed this week that more countries will be added to the Abraham Accords, the series...

Japan’s cherry blossom season officially begins in Tokyo
Japan's cherry blossom season begins as first blooms appear in Tokyo

TOKYO, Japan: This week, Japan's cherry blossom season officially began as experts confirmed the first blooms in Tokyo. A specialist...

67,000 Seek U.S. Refugee Status Under Trump’s White Minority Plan
67,000 white South Africans favor Trump's plan for refugee status

CAPE TOWN, South Africa: The U.S. Embassy in South Africa said it received a list of over 67,000 people interested in refugee status...

North Carolina court allows suit over teen’s unapproved COVID shot
North Carolina court allows family to sue over unwanted COVID-19 shot

RALEIGH, North Carolina: North Carolina's highest court has ruled that a mother and her teenage son can pursue a lawsuit over a COVID-19...

Business

Section
Regulatory win in India paves way for Starlink's expansion
For Musk's Starlink, India approval could unlock emerging markets

BENGALURU, India: A major regulatory breakthrough in India could mark a turning point for Starlink, Elon Musk's satellite internet...

U.S. stocks plummet on Trump trade policies, techs worst hit
Dow Jones tumbles 716 points as Trump's trade war escalates

NEW YORK, New York - Renewed fears about inflation, and U.S. Donald Trump's trade policies say American markets take a deep dive Friday....

Segway recalls 220,000 scooters over fall hazard
Segway recalls 220,000 scooters after reporting 20 injuries

NEW YORK CITY, New York: Segway is recalling about 220,000 scooters in the U.S. because of a safety issue that can cause riders to...

China reassures Apple CEO Tim Cook amid geopolitical tensions
Apple welcome to expand investment, Chinese minister tells Tim Cook

BEIJING, China: As global tech firms navigate rising geopolitical tensions, China has extended a warm signal to Apple, one of its most...

Automakers lead U.S. stock markets lower after tariff hit
Wall Street rattled by 25% tariff on all cars made outside U.S.

NEW YORK, New York - Shares in automakers fell sharply Thursday after U.S.President Donald Trump imposed a 25 percent tariff on all...

Ford F-150 under investigation for transmission defects
US opens probe into 1.3 million Ford F-150 trucks over gear shift

WASHINGTON, D.C.: Federal safety regulators have launched a new investigation into Ford's best-selling F-150 pickup trucks after receiving...